Cardiotoxicity risk assessment using in silico model of iPS cell-derived cardiomyocyte

Abstract

To improve the cost-efficiency of drug development, both human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and in silico have been recently employed on the evaluations of safety pharmacology and toxicity tests. On the other hand, it has become to know that the electrophysiological properties of hiPSC-CM are different from the original cardiomyocytes. Hereby, we constructed virtual hiPSC-CM (viPS) and found various differences between them in the molecular, cell, and tissue levels. The viPS is very useful for the safety pharmacology and toxicity tests in the future.